Figure 1.

Unsupervised principal component analysis (PCA) performed on the total number of lipids identified in (A) stage 5 chronic kidney disease (CKD5) (red), cardiovascular disease (CVD) (blue), stage 1 and 2 chronic kidney disease (CKD1-2) (black), and healthy volunteers (HVs) (green) experimental groups. (B) To highlight the observed differences, only CKD5 (red) and CVD (blue) are marked. Other groups are presented in grey. (C) Hierarchical clustering analysis of identified lipid classes. PC, PC-O- phosphatidylcholines; PE, PE-O—phosphatidylethanolamines; PI—phosphatidylinositols; LPC—lysophosphatidylcholines; LPE—lysophosphatidylethanolamines; PS—phosphatidylserines; SM—sphingomyelins; Cer—ceramides; HexCer—hexosylceramides; TAG—triacylglycerols; DAG—diacylglycerols; CE—cholesterol and cholesteryl esters.